Lv44
630 积分 2026-07-08 加入
The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma
3天前
已完结
Survival Outcomes in Stage III to IV Melanoma Before and After the Immunotherapy Era
3天前
已关闭
Survival Outcomes in Stage III to IV Melanoma Before and After the Immunotherapy Era
3天前
已关闭
Immune checkpoint inhibitors in advanced cutaneous melanoma: a systematic review and meta-analysis of efficacy and review of characteristics
19天前
已完结
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
30天前
已完结
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizu mab, dabrafenib, and trametinib in BRAF-mutant melanoma. Journal For ImmunoTherapy Of Cancer
1个月前
已完结
Adjuvant pembroli zumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
1个月前
已完结
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
1个月前
已完结
Adjuvant ipilimu mab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol
1个月前
已完结
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
1个月前
已完结
皖公网安备34019202002308
